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A normal vitamin D status is essential for human health.
Vitamin D deficiency is a recognized risk factor for all-cause
mortality in normal individuals and in chronic kidney disease
(CKD) patients. The link between vitamin D deficiency and
death is a defective activation of the vitamin D receptor
(VDR) by 1,25-dihydroxyvitamin D (calcitriol, the vitamin D
hormone) to induce/repress genes that maintain mineral
homeostasis and skeletal integrity, and prevent secondary
hyperparathyroidism, hypertension, immune disorders, and
renal and cardiovascular (CV) damage. The kidney is the main
site for the conversion of 25-hydroxyvitamin D (25D) to
circulating calcitriol, and therefore essential for the health
benefits of endocrine VDR activation. The kidney is also
essential for the uptake of 25D from the glomerular
ultrafiltrate for its recycling to the circulation to maintain
serum 25D levels, extrarenal calcitriol synthesis, and the
prosurvival benefits of autocrine/paracrine VDR activation.
Indeed, both calcitriol and vitamin D deficiency increase
progressively in the course of CKD, and associate directly
with accelerated disease progression and death. Therefore,
the safe correction of calcitriol and vitamin D deficiency/
insufficiency is becoming a high priority among
nephrologists. This review updates the pathophysiology
behind 25D and calcitriol deficiency and impaired VDR
activation in CKD, the adequacy of current recommendations
for vitamin D supplementation, and potential markers of the
efficacy of therapy to prevent or slow the development of
renal and CV lesions unrelated to parathyroid hormone
suppression, a knowledge required for the design of trials
to obtain evidence-based recommendations for vitamin D
and calcitriol replacement at all stages of CKD.
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VDR ACTIVATION AND HUMAN HEALTH
The health benefits of a normal vitamin D status go far
beyond the prevention of disorders in mineral homeostasis,
bone remodeling, or the development of secondary hyper-
parathyroidism (SHPT), with important renal and cardio-
vascular (CV) protective actions that contribute to the strong
association between vitamin D deficiency and all-cause
mortality in the general population (Figure 1).1,2 Most
vitamin D actions require the activation of the vitamin D
receptor (VDR) by 1,25-dihydroxyvitamin D, also called
calcitriol or 1,25D, the most active native vitamin D
metabolite and a potent steroid hormone.3 Similar to other
steroid hormones, calcitriol binding to the VDR is the initial
step to activate the VDR to induce or repress the expression
of genes that maintain mineral homeostasis and skeletal
health, as well as immune, renal, and CV function. Indeed,
VDR-regulated gene products tightly coordinate intestinal
calcium and phosphate absorption, bone metabolism, renal
calcium and phosphate reabsorption, and parathyroid
function to prevent or slow the development of SHPT,
phosphate retention, and soft-tissue calcifications, and also
inhibit or attenuate the activation of the renin–angiotensin
system, systemic inflammation, and proteinuria, three
important contributors to renal and CV damage and
enhanced mortality rates.4
The kidney is the main site for the conversion of
25-hydroxyvitamin D (25D) to circulating calcitriol. In fact,
in the course of chronic kidney disease (CKD), progressive
reductions in serum calcitriol and endocrine VDR activation
are important contributors to the development of SHPT,
vascular calcifications, and high mortality rates.5 Therefore,
calcitriol replacement with either calcitriol or its analogs has
been the therapy of choice to prevent or slow the progression
of SHPT and its associated adverse effects.5 Large retro-
spective trials in hemodialysis patients have suggested that
calcitriol replacement confers a survival advantage unrelated
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to its efficacy (or the lack of it) to suppress parathyroid
hormone (PTH).6 These studies have led to the identification
of the most critical renal and cardioprotective properties of
selective VDR activation in preclinical and small clinical
trials, including the inhibition of the renin–angiotensin
system, proteinuria, and systemic inflammation (reviewed
in ref. 4). However, the initial enthusiasm to start calcitriol
replacement earlier or to prolong its use to improve
outcomes independently of its efficacy to suppress PTH
was diminished after the reports from the Cochrane Group7,8
of the lack of evidence from adequately powered prospective
studies in support of the survival effects of VDR activation in
predialysis and dialysis patients.
An important consideration that could improve the
outcomes of exclusive calcitriol replacement is the main-
tenance of a normal vitamin D status: the kidney is not
unique in the capacity to produce calcitriol, nor is endocrine
VDR activation the only contributor to calcitriol prosurvival
properties. Indeed, in the general population with normal
renal function and normal serum calcitriol levels, vitamin D
deficiency causes SHPT, bone loss, and strongly associates
with a higher risk for hypertension, proteinuria, CV lesions,
and higher rates of CV mortality.9 The contribution of
non-renal cells to systemic calcitriol levels is negligible in
individuals with normal kidney function, which underscores
the critical role of autocrine/paracrine VDR activation by
calcitriol synthesized locally in the cell-specific prosurvival
actions of a normal vitamin D status. In CKD patients,
vitamin D deficiency is also a strong predictor of accelerated
renal disease progression and death.10 In view of the striking
incidence of vitamin D deficiency/insufficiency among CKD
patients, the safe correction of vitamin D and calcitriol
deficiency/insufficiency is becoming a high priority for
nephrologists. The implementation of vitamin D and/or
calcitriol replacement that safely improves the prosurvival
actions of selective VDR activation beyond PTH suppression
at all stages of CKD requires an update of our understanding
of the pathogenesis of calcitriol and vitamin D deficiency/
insufficiency and impaired VDR activation.
CRITICAL ROLE OF THE KIDNEY IN AUTOCRINE/
PARACRINE VDR ACTIVATION
Until recently, our understanding of the pathogenesis of
calcitriol deficiency in the course of CKD was the progressive
loss of renal 1-hydroxylase with the reductions in functional
renal mass, and the inhibition of remnant 1-hydroxylase
activity by elevations in serum levels of uremic toxins, PTH
fragments, and fibroblast growth factor (FGF)-23 (reviewed
in ref. 11). However, defects in renal uptake of 25D in CKD
are important contributors to systemic calcitriol deficiency,
and also key determinants of 25D deficiency because renal
proximal tubular cells obtain the 25D for its conversion to
calcitriol not from the blood but from the glomerular
ultrafiltrate.12 Figure 2 shows that megalin, a multiligand
receptor, mediates the active process of endocytosis of the
filtered 25D bound to its carrier, the vitamin D-binding
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Figure 1 |Health benefits of vitamin D receptor (VDR) activation. Vitamin D actions require vitamin D activation to its hormonal form,
1,25-dihydroxyvitamin D (calcitriol; 1,25D), by renal and extrarenal 1-hydroxylases to bind and activate the VDR in an endocrine and/or
autocrine manner, respectively. The precursor of 1,25D, 25-hydroxyvitamin D (25D), can also bind and activate the VDR with a much lower
potency. Upon activation, ligand-bound VDR functions as a transcription factor to regulate the expression of genes involved in vitamin D
maintenance of mineral homeostasis, skeletal health, and renal and cardiovascular protection. B, basal transcription factor; Ca, calcium;
CoReg, coregulator molecule; FGF-23, fibroblast growth factor-23; P, phosphorus; RAS, renin–angiotensin system; RXR, retinoid x receptor;
VDRE, vitamin D-responsive element; 25D3, 25-hydroxyvitamin D3; 1,25D3, 1,25-dihydroxyvitamin D3.
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protein, from the glomerular ultrafiltrate. Once inside
proximal tubular cells, 25D is either delivered to 1-hydro-
xylase for its conversion to calcitriol or recycled back to
the circulation to maintain normal serum 25D and the
appropriate supply of substrate to non-renal cells expressing
1-hydroxylase for local calcitriol production and autocrine
VDR activation. The key contribution of megalin-mediated
recycling of 25D to maintain normal serum levels of 25D was
conclusively demonstrated in the megalin-null mouse, in
which severe vitamin D deficiency occurs in spite of normal
renal function.12 Importantly, renal megalin is induced by
calcitriol.13 Therefore, vitamin D deficiency/insufficiency
in normal individuals results in reduced 25D levels in
the glomerular ultrafiltrate in spite of normal glomerular
filtration rates, causing a vicious cycle for progressive
deterioration of renal calcitriol synthesis and megalin
expression. The latter can account for the strong association
between vitamin D deficiency and albuminuria in normal
individuals,14 as megalin also mediates urinary albumin
reabsorption.
In CKD, progressive reductions in glomerular filtration
rate and also in renal megalin expression15 further aggravate
the low renal uptake of 25D caused by vitamin D deficiency/
insufficiency, decreasing calcitriol production by the remnant
1-hydroxylase and, consequently, renal autocrine VDR
activation. Defective VDR activation of renal megalin in
CKD patients may partially account not only for the degree
of albuminuria, but also for phosphate retention in spite
of high serum PTH. Indeed, a specific deletion of megalin
expression in the kidney eliminates the phosphaturic res-
ponse to PTH because megalin mediates the internalization
of the sodium–phosphate cotransporter NaPi2a required for
PTH to stop renal phosphate reabsorption.16
Low serum 25D levels are not the only impediment
to maintain normal autocrine VDR activation in CKD
(Figure 2). Peripheral blood mononuclear cells from patients
in hemodialysis elicit ex vivo a markedly impaired uptake
of 25D.17 Thus, vitamin D deficiency contributes to the
progressive reductions of serum calcitriol in the course of
CKD by impairing both renal and extrarenal calcitriol
production. The safe correction of vitamin D deficiency at
early stages of CKD could help prevent/slow the loss of the
renal and cardioprotective properties of endocrine and/or
autocrine/paracrine VDR activation.
CONSIDERATIONS FOR THE SAFE CORRECTION OF
VITAMIN D DEFICIENCY IN CKD
Native vitamin D is available in two distinct forms:
ergocalciferol (vitamin D2) and cholecalciferol (vitamin
D3). Studies in normal individuals have demonstrated that
vitamin D2 has a lower efficacy for a sustained correction of
25D levels compared with vitamin D3.
18 Both vitamin D
forms elicit similar elevations in serum vitamin D levels upon
a single oral dose of 100,000 IU and a similar disappearance
from the circulation. However, whereas vitamin D3 dosage
results in a sustained increase in serum 25D3 for 30 days,
upon vitamin D2 administration 25D2 levels decrease to
baseline values within 2 weeks.18 Importantly, switching the
frequency for vitamin D2 administration from bolus to daily
can enhance its efficacy to sustain serum 25D2 levels similar
to that of vitamin D3.
19 25D2 and 25D3 have the same
potency in humans. An additional advantage of lower daily
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Figure 2 |Critical role of normal kidney function in vitamin D receptor (VDR) activation. The endocytic receptor megalin in renal
proximal tubular cells is required for the uptake of 25-hydroxyvitamin D (25D; ) bound to its carrier, the vitamin D-binding protein
(DBP; ) from the glomerular ultrafiltrate. Once inside proximal tubular cells, 25D is either delivered to renal 1-hydroxylase for its conversion
to 1,25-dihydroxyvitamin D (calcitriol; 1,25D; ), to maintain 1,25D production and renal and endocrine VDR activation, or recycled back to
the blood to maintain serum 25D levels and to supply extrarenal 1-hydroxylases for its conversion to 1,25D for autocrine VDR activation.
Chronic kidney disease (red arrows) reduces not only renal 1-hydroxylase and the amount of filtered 25D but also renal megalin content and
the uptake of 25D by monocytes–macrophages, markedly impairing both endocrine and autocrine VDR activation. IDBP3, intracellular
vitamin D binding protein 3; PTH, parathyroid hormone.
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doses of vitamin D is that the rate of conversion of vitamin
D2 or D3 to 25D2/3 is much higher for doses below 4000 IU.
20
These studies, however, may not reflect the efficacy of a low
daily dose of vitamin D to correct 25D deficiency in
predialysis and dialysis patients because CKD may alter both
the metabolism of vitamin D2 and D3 and the rate of
conversion of vitamin D to 25D.
In Europe, 25D is available for oral administration;
however, caution is warranted with dose frequency because
there is no conversion required and also because the half-
life of 25D is longer (15–18 days) than that of vitamin D
(3–7 days), which could result in rapid accumulation to levels
above the normal upper range (150 ng/ml).
Importantly, the radioimmunoassays and enzyme-linked
immunosorbent assays available to measure 25D2/3 have a
100% cross-reactivity with 24,25-dihydroxyvitamin D2/3,
which could lead to an overestimation of the efficacy of
vitamin D supplementation to correct serum 25D levels in
CKD patients in whom 24,25(OH)2D synthesis is induced
by high serum FGF-23 or calcitriol replacement therapy
(reviewed in ref. 11).
SAFETY AND EFFICACY OF VITAMIN D SUPPLEMENTATION
TO IMPROVE AUTOCRINE VDR ACTIVATION
The contribution of vitamin D deficiency to the low serum
calcitriol of CKD patients was conclusively demonstrated in
the 1980s. Administration of 25D can normalize the very
low calcitriol levels of patients with a glomerular filtration
rate below 25ml/min undergoing hemodialysis,21 and also
the almost undetectable serum calcitriol of bilaterally
nephrectomized patients.22 These findings suggest that at
earlier stages of CKD, vitamin D supplementation that
effectively enhances serum 25D levels will increase the
proportion of D-binding protein carrying filtered 25D and
the levels of 25D available for renal and extrarenal calcitriol
synthesis. The lower the glomerular filtration rate, remnant
renal 1-hydroxylase, and megalin content, and the higher
serum FGF-23 levels, the higher must be the serum 25D levels
to normalize serum calcitriol from renal and extrarenal
sources. In fact, whereas 4 ng/ml of 25D is sufficient to
maintain normal serum calcitriol in individuals with normal
kidney function,23 the requirements increase to levels of 25D
above 100 ng/ml in hemodialysis patients, and above 200 ng/
ml in anephric patients, in whom extrarenal 1-hydroxylases
are the only contributors to systemic calcitriol. The high
levels of 25D required to normalize serum calcitriol may
compromise rather than improve survival. In fact, in a group
of normal women, serum 25D levels above 50 ng/ml start
reversing the decline of mortality rates with the correction of
vitamin D deficiency.24
Studies on the efficacy of 25D supplementation to
improve autocrine VDR activation have been limited to
PTH suppression. In transplant recipients, doses of vitamin
D of 100,000 IU twice a month are necessary to control PTH.
Importantly, the efficacy of the same dosage decreases when
provided only monthly.25 In CKD stages 3 and 4, only 50% of
the patients in whom serum 25D levels increase above
35 ng/ml in response to 50,000 IU of ergocalciferol adminis-
tered twice a month can suppress PTH.26 Reductions
in parathyroid megalin27 may add to the impaired renal
uptake of 25D to increase the requirements of vitamin D
supplementation to effectively suppress PTH. In view of the
adverse effects reported for 25D levels above 50 ng/ml in
women with normal serum calcitriol,24 transient increases in
serum 25D above 50 ng/ml after a high bolus of ‘inactive’
vitamin D can exert detrimental effects on survival through
direct activation of the VDR (Figure 1). These adverse effects
may be overlooked if changes in serum phosphate and
calcium levels are measured a month after dosage. The long-
term beneficial or detrimental effects of prolonged supple-
mentation with high bolus doses of vitamin D need to be
tested in prospective trials.
Importantly, in a recent report in CKD stages 3 and 4,
daily dosage of cholecalciferol of 4000 IU/day for a month,
followed by 2000 IU for two additional months was sufficient
to increase 25D levels above 37 ng/ml and to normalize serum
calcitriol; however, it failed to reduce PTH, proteinuria, or
blood pressure.28 These findings support the higher conver-
sion rates of vitamin D to 25D for low daily doses and
demonstrate that the correction of serum calcitriol and/or
25D levels is inaccurate to monitor the efficacy of vitamin D
supplementation to improve prosurvival actions of VDR
activation unrelated to PTH suppression.
The correction of calcitriol deficiency can lower the
amount of vitamin D supplementation required to improve
extrarenal calcitriol synthesis and autocrine VDR activation.
In hemodialysis patients, the correction of the low serum
calcitriol levels through intravenous calcitriol administration
corrects the impaired uptake of 25D by peripheral blood
mononuclear cells.17 Thus, in CKD patients, vitamin D
supplementation corrects the impaired renal uptake of 25D
to maintain renal calcitriol synthesis and serum 25D levels for
extrarenal calcitriol production. In turn, calcitriol replace-
ment to normalize serum calcitriol corrects the defective
uptake of 25D by non-renal cells bearing 1-hydroxylase.
Taken together, these findings support the benefits of
combined vitamin D and calcitriol replacement. Indeed,
preliminary studies in 5/6 nephrectomized rats demonstrated
the benefits of combination therapy with 25D (at weekly
doses sufficient to increase serum levels above 35 ng/ml) and
paricalcitol (at a dose insufficient to suppress PTH),
compared with monotherapy either to prevent or slow
proteinuria and aortic calcifications.29 These preclinical
studies support dual benefits of vitamin D and calcitriol
replacement: low doses of selective VDR activators may
improve the renal and CV outcomes of vitamin D
supplementation at early stages of CKD. In addition, vitamin
D supplementation may enhance the renal and cardiopro-
tective efficacy of low doses of paricalcitol. The latter suggests
that the simple correction of vitamin D deficiency in vitamin
D-deficient patients in the Selective Vitamin D Receptor
(VDR) Activator for Albuminuria Lowering (VITAL) Study
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might have increased the efficacy of 1 mg of paricalcitol to
control proteinuria.30 However, the design of safe trials to
provide evidence-based recommendations for combined
vitamin D and calcitriol replacement at all stages of kidney
disease is a very difficult task. Not only can the high levels of
25D required to enhance autocrine VDR activation induce
toxicity at non-hypercalcemic doses of calcitriol or selective
VDR activators, but also the high levels of selective activators
required to suppress PTH or induce renal and CV protection
in tissues with reduced VDR compromise rather than
enhance extrarenal calcitriol production by suppressing
1-hydroxylase expression,17 and also by enhancing the
degradation of 25D, calcitriol, and its analogs, thereby
reducing both autocrine and paracrine VDR activation. The
achievement of the appropriate balance of serum levels of
25D and selective VDR activators to maximize VDR
activation requires the identification of accurate markers
of renal and CV lesions.
TACE ACTIVATION CAUSES RENAL AND CV DAMAGE
Increases in renal levels and activity of tumor necrosis factor-
a (TNFa)-converting enzyme (TACE, also called ADAM17)
and TACE-mediated release of transforming growth factor-a
are the cause of proteinuria, glomerular sclerosis, mono-
nuclear cell infiltration, tubular hyperplasia, and fibrosis
upon nephron reduction, or prolonged exposure to angio-
tensin II in mice (Figure 3).31 Similar increases in TACE and
transforming growth factor-a occur in fibrotic and inflam-
matory human kidney disease.32 Upon the initial mechanism
triggering renal TACE activation, TACE-mediated release to
the circulation of the profibrotic and proinflammatory
cytokines soluble TNFa, soluble intercellular cell adhesion
molecule (sICAM)-1, and soluble vascular cell adhesion
molecule (sVCAM)-1 from their transmembrane precursors
causes systemic inflammation and aggravates renal and CV
damage (reviewed in ref. 29). Increases in TACE and the
release of TNFa are sufficient to explain the high risk of
CV mortality in CKD. TNFa is a well-recognized cause of
systemic inflammation, atherosclerosis, and vascular calcifi-
cations.33 More significantly, polymorphisms of TACE that
mildly elevate serum TNFa are associated with a higher risk
of death from CV disease in normal individuals.34 Further-
more, increases in serum sICAM-1 and sVCAM-1 levels in
transplant recipients are better indicators than proteinuria of
poor prognosis.35 The accuracy of the prevention/attenuation
of increases in renal and monocyte TACE and/or serum
markers of renal TACE activation to monitor the efficacy of
therapy was tested in rat CKD and in hemodialysis patients.
In rats, the higher efficacy over monotherapy of the 25D and
paricalcitol combination to prevent or slow proteinuria and
aortic calcification was associated with its higher potency to
reduce TACE expression in the kidney and in monocyte/
macrophages.29 Studies in hemodialysis patients demon-
strated a threefold enhancement of TACE expression in
peripheral monocytes and in serum levels of TNFa, ICAM-1,
and VCAM-1 compared with normal controls, and the
efficacy of the combination of vitamin D supplementation
and paricalcitol to synergize with anti-renin–angiotensin
system therapy to reduce TACE expression and activity.36
Thus, TACE expression in monocytes and serum markers of
tissue TACE activation have the potential to help monitor the
severity of renal and CV lesions and systemic inflammation
and its changes with therapeutic interventions with anti-
renin–angiotensin system and/or vitamin D therapy.
In summary, normal kidney function is essential to
maintain not only serum calcitriol levels but also serum
25D levels, and thus the health benefits of both endocrine
and autocrine VDR activation. CKD induces severe abnorm-
alities to the complex regulation of renal and extrarenal
calcitriol synthesis and catabolism that impede providing
simple safe recommendations to improve clinical outcomes
at all stages of CKD. Furthermore, the design of the much-
needed clinical trials for safe and evidence-based recommen-
dations also requires previous testing of the accuracy
of available markers of renal and CV lesions unrelated to
PTH suppression to monitor the efficacy of therapy. All tools
to address this overwhelming challenge for nephrologists are
at hand.
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